tiprankstipranks
Trending News
More News >
Vicore Pharma Holding AB (SE:VICO)
:VICO
Advertisement

Vicore Pharma Holding AB (VICO) AI Stock Analysis

Compare
0 Followers

Top Page

SE:VICO

Vicore Pharma Holding AB

(Frankfurt:VICO)

Rating:45Neutral
Price Target:
Vicore Pharma Holding AB's stock is evaluated at a moderate level, reflecting its strong liquidity and financial resilience amidst continued net losses typical for biotech R&D phases. The technical analysis indicates potential short-term stability, while valuation remains tricky due to the negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Vicore Pharma Holding AB (VICO) vs. iShares MSCI Sweden ETF (EWD)

Vicore Pharma Holding AB Business Overview & Revenue Model

Company DescriptionVicore Pharma Holding AB (VICO) is a Sweden-based pharmaceutical company focused on the development of innovative therapies for rare lung diseases and related indications. The company's core products are centered around its proprietary angiotensin II type 2 receptor (AT2R) agonist platform, which aims to address unmet medical needs in pulmonary and fibrotic diseases. Vicore Pharma's lead product candidate, VP01 (C21), is being developed for conditions such as idiopathic pulmonary fibrosis (IPF) and COVID-19-induced acute respiratory distress syndrome (ARDS).
How the Company Makes MoneyVicore Pharma Holding AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's revenue model is largely dependent on the successful progression of its drug candidates through clinical trials, leading to potential licensing agreements, partnerships, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies. Vicore Pharma may also seek funding through grants and public or private investments to support its research and development activities.

Vicore Pharma Holding AB Financial Statement Overview

Summary
Vicore Pharma Holding AB demonstrates financial resilience with strong cash positions and no debt, but faces profitability challenges common in early-stage biotech firms. The negative cash flow from operations and reliance on equity financing highlights the company's focus on R&D without immediate revenue returns.
Income Statement
30
Negative
Vicore Pharma Holding AB has shown significant challenges in profitability. The net profit margin remains negative due to high operating losses, despite a revenue increase in 2024. The gross profit margin is positive but primarily due to the revenue recognition without associated costs. The company exhibits a history of net losses, which is typical for early-stage biotech firms focusing on R&D.
Balance Sheet
45
Neutral
The balance sheet is relatively strong with no debt and substantial cash reserves, indicating good liquidity. The equity ratio is high, which is positive for financial stability. However, the continuous accumulation of losses affects the return on equity, which remains negative. The company maintains a strong equity position, providing a buffer against operational risks.
Cash Flow
40
Negative
Cash flow from operations is consistently negative, reflecting the high costs associated with biotech R&D activities. Despite negative free cash flow, the company has managed to increase cash reserves significantly through financing activities, improving liquidity. The cash flow to net income ratios indicate reliance on financing rather than operational cash generation.
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Vicore Pharma Holding AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.66
Price Trends
50DMA
8.20
Positive
100DMA
7.78
Positive
200DMA
8.05
Positive
Market Momentum
MACD
0.17
Negative
RSI
65.02
Neutral
STOCH
77.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VICO, the sentiment is Positive. The current price of 8.66 is above the 20-day moving average (MA) of 7.96, above the 50-day MA of 8.20, and above the 200-day MA of 8.05, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 65.02 is Neutral, neither overbought nor oversold. The STOCH value of 77.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VICO.

Vicore Pharma Holding AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
kr1.21B4.39152.78%1533.99%
57
Neutral
kr2.64B-45.80%-0.57%-39.92%
52
Neutral
kr5.61B10.39-63.86%1.96%27.11%26.73%
49
Neutral
kr2.31B
20.12%40.54%
48
Neutral
kr1.09B-48.22%67.70%
47
Neutral
kr1.92B-42.24%-19.44%
45
Neutral
kr2.01B-40.15%63.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:VICO
Vicore Pharma Holding AB
8.92
-9.00
-50.23%
SE:HNSA
Hansa Biopharma AB
27.30
-14.16
-34.15%
SE:BINV
BioInvent International AB
38.10
-2.60
-6.39%
SE:SANION
Saniona AB
8.50
3.76
79.32%
SE:XSPRAY
Xspray Pharma AB
51.80
-0.08
-0.15%
SE:SYNACT
SynAct Pharma AB
21.95
13.55
161.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2025